SpyBiotech

The company's business model revolves around developing its own vaccine candidates and licensing its platform technology to partners. A key partnership includes an exclusive global licensing agreement with the Serum Institute of India to develop a COVID-19 vaccine, which has undergone clinical trials. SpyBiotech's primary clients are in the global healthcare and biopharmaceutical sectors. The company's main product is its vaccine platform, which includes the SPYVLP (Virus-Like Particle) and SPYVECTOR technologies. This platform addresses a common problem in vaccine development where traditional methods of attaching antigens to delivery particles can be imprecise and damage the components, rendering the vaccine ineffective. SpyBiotech's technology creates a spontaneous and irreversible covalent bond, allowing for controlled and stable vaccine assembly that can induce a robust immune response.

Since its inception with seed funding from Oxford Science Enterprises and GV (formerly Google Ventures), SpyBiotech has secured significant financing, including a $32.5 million Series A round in 2021 and a $4.09 million grant from the Bill & Melinda Gates Foundation in 2023. These funds are advancing the clinical development of its vaccine pipeline. The company's lead internal candidate is a vaccine for human cytomegalovirus (HCMV), which entered Phase I clinical trials in late 2023. SpyBiotech is also developing vaccines for other targets, including Epstein-Barr Virus (EBV).